New York State Common Retirement Fund Sells 14,949 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New York State Common Retirement Fund reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 181,404 shares of the medical equipment provider’s stock after selling 14,949 shares during the period. New York State Common Retirement Fund owned approximately 0.27% of Lantheus worth $12,604,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Covestor Ltd increased its stake in Lantheus by 102.5% in the second quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 164 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Lantheus by 115.7% in the second quarter. Quadrant Capital Group LLC now owns 496 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 266 shares in the last quarter. Finally, Coppell Advisory Solutions LLC bought a new stake in Lantheus in the second quarter valued at approximately $46,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In related news, CEO Mary Anne Heino sold 11,780 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.72, for a total transaction of $750,621.60. Following the transaction, the chief executive officer now directly owns 317,687 shares of the company’s stock, valued at $20,243,015.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Lantheus news, CEO Mary Anne Heino sold 11,780 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.72, for a total value of $750,621.60. Following the transaction, the chief executive officer now directly owns 317,687 shares of the company’s stock, valued at $20,243,015.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Paul Blanchfield sold 1,500 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $67.96, for a total transaction of $101,940.00. Following the completion of the transaction, the president now directly owns 88,651 shares in the company, valued at $6,024,721.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,962 shares of company stock worth $893,338. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.7 %

NASDAQ:LNTH opened at $54.99 on Wednesday. The company has a market cap of $3.77 billion, a PE ratio of 38.45 and a beta of 0.53. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $100.85. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.37 and a quick ratio of 5.05. The firm’s 50 day simple moving average is $61.76 and its 200 day simple moving average is $66.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LNTH shares. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. JMP Securities lowered their price objective on shares of Lantheus from $130.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, November 3rd. Brookline Capital Management started coverage on shares of Lantheus in a research report on Thursday, November 30th. They set a “buy” rating and a $100.00 price objective for the company. B. Riley lowered their price objective on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research report on Wednesday, January 10th. Finally, TheStreet downgraded shares of Lantheus from a “b-” rating to a “c” rating in a research report on Monday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $108.14.

View Our Latest Stock Analysis on Lantheus

Lantheus Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Featured Articles

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.